BeyondSpring updates Plinabulin data, names new CEO, reports Q2 2026 results
The company highlighted ASCO and AACR data supporting Plinabulin and confirmed a July 1 leadership change as it works toward starting the Phase 3 DUBLIN-4 trial.
BeyondSpring Inc. (NASDAQ: BYSI) reported second-quarter 2026 results on August 14, 2026, alongside updates on its lead drug candidate Plinabulin and a leadership transition.
At the ASCO 2026 meeting, investigators presented updated data from the Phase 2 "303 Study," which is testing Plinabulin combined with docetaxel and pembrolizumab in patients with metastatic non-small cell lung cancer (NSCLC) who developed resistance after first-line immune checkpoint inhibitor therapy. The trial enrolled 47 patients evaluating the Plinabulin/docetaxel and pembrolizumab combination for durable response and survival benefit in this post-ICI setting.1 Based on data collected through February 28, 2026, median progression-free survival reached 7.0 months, median duration of response was 9.3 months, the disease control rate was 79.5%, and the confirmed objective response rate was 18.2%; one-year survival stood at 78.1% and two-year survival at 58.0%, with median overall survival not yet reached after roughly 28.8 months of follow-up.1 Safety was described as generally manageable, with signs of immune activation including higher activated CD4+ and CD8+ T-cell counts and elevated white blood cell, neutrophil, and platelet levels.1
At AACR 2026, the company presented preclinical findings suggesting that pairing Plinabulin with approved TOP1-based antibody-drug conjugates, including datopotamab deruxtecan and trastuzumab deruxtecan, improved complete tumor regression and survival in models, both with and without PD-1/PD-L1 inhibition.1 The combination also showed better tolerability and a higher CD8+ T-cell-to-Treg ratio, pointing to an immune-based mechanism.1
On the pipeline, BeyondSpring said DUBLIN-4 is a planned 442-patient, randomized, double-blind Phase 3 study of Plinabulin plus docetaxel in non-squamous, EGFR wild-type NSCLC patients who progressed on PD-1/PD-L1 therapy, designed to confirm survival and tolerability results from the earlier DUBLIN-3 study published in The Lancet Respiratory Medicine in 2024.1
Effective July 1, 2026, Min Qiu became CEO with a mandate to advance DUBLIN-4 and build the company's partner and investor base.1 Dr. Jiangwen (Jen) Majeti was named Vice Chairman and Na Li was named Chief Financial Officer.1 Co-founder Dr. Lan Huang remains Chairman while focusing her executive role at SEED Therapeutics.1
Financially, cash, cash equivalents, and short-term investments totaled $6.5 million as of June 30, 2026, down from $12.6 million at the end of 2025.1 Net loss for the first six months of 2026 was $4.1 million, compared with $4.5 million a year earlier.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.